{"id":"axitinib-tablets","safety":{"commonSideEffects":[{"rate":"38%","effect":"Hypertension"},{"rate":"37%","effect":"Fatigue"},{"rate":"29%","effect":"Diarrhea"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"featherless-qwen","explanation":"By inhibiting these receptors, axitinib blocks the formation of new blood vessels that tumors need to grow and spread, thereby slowing tumor progression.","oneSentence":"Axitinib is a selective inhibitor of vascular endothelial growth factor receptors (VEGFR-1, VEGFR-2, and VEGFR-3).","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T04:57:24.079Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Advanced renal cell carcinoma"}]},"trialDetails":[{"nctId":"NCT07123090","phase":"PHASE2","title":"A Study of Sasanlimab, Palbociclib and Axitinib in Metastatic Renal Cell Carcinoma","status":"RECRUITING","sponsor":"Stephanie Berg","startDate":"2025-11-24","conditions":"Metastatic Renal Cell Carcinoma, Metastatic Renal Cancer, Renal Cell Carcinoma","enrollment":25},{"nctId":"NCT03839498","phase":"PHASE2","title":"Study of Axitinib (AG-013736) With Evaluation of the VEGF-pathway in Pheochromocytoma/Paraganglioma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Columbia University","startDate":"2019-01-22","conditions":"Pheochromocytoma, Paraganglioma","enrollment":6},{"nctId":"NCT02853331","phase":"PHASE3","title":"Study to Evaluate the Efficacy and Safety of Pembrolizumab (MK-3475) in Combination With Axitinib Versus Sunitinib Monotherapy in Participants With Renal Cell Carcinoma (MK-3475-426/KEYNOTE-426)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2016-09-16","conditions":"Renal Cell Carcinoma","enrollment":861},{"nctId":"NCT04585815","phase":"PHASE1, PHASE2","title":"Study of Immunotherapy (Sasanlimab) in Combination With Targeted Therapies in People With Advanced Non-small Cell Lung Cancer (NSCLC) (Landscape 1011 Study)","status":"TERMINATED","sponsor":"Pfizer","startDate":"2020-11-10","conditions":"Carcinoma, Non-Small-Cell Lung","enrollment":34},{"nctId":"NCT04394975","phase":"PHASE3","title":"Study to Evaluate the Efficacy and Safety of Toripalimab in Combination With Axitinib Versus Sunitinib Monotherapy in Advanced Renal Cell Cancer","status":"COMPLETED","sponsor":"Shanghai Junshi Bioscience Co., Ltd.","startDate":"2020-08-20","conditions":"Primary Disease: Unresectable or Metastatic Renal Cell Carcinoma Focus of the Study:PFS Assessed by IRC Per RECIST 1.1","enrollment":421},{"nctId":"NCT03438708","phase":"PHASE2","title":"Prior Axitinib as a Determinant of Outcome of Renal Surgery","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of California, San Diego","startDate":"2018-03-05","conditions":"Clear Cell Renal Cell Carcinoma","enrollment":22},{"nctId":"NCT04640545","phase":"PHASE1","title":"A Study to Assess LBL-007 in Combination With Toripalimab and Axitinib Tablets Subjects With Advanced Melanoma","status":"COMPLETED","sponsor":"Nanjing Leads Biolabs Co.,Ltd","startDate":"2020-05-12","conditions":"Advanced Melanoma","enrollment":79},{"nctId":"NCT07159191","phase":"PHASE2","title":"Envafolimab Combined With Axitinib as First-Line Treatment for Patients With Advanced Renal Cell Carcinoma","status":"NOT_YET_RECRUITING","sponsor":"Peking Union Medical College Hospital","startDate":"2025-09-01","conditions":"Advanced Renal Cell Carcinoma (aRCC)","enrollment":30},{"nctId":"NCT02597322","phase":"PHASE2","title":"Study of Axitinib for Downstaging Large Renal Tumors Not Primarily Suitable for Partial Nephrectomy (AXIPAN)","status":"COMPLETED","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2012-02","conditions":"cT2a N0NxM0 Renal Tumor","enrollment":21},{"nctId":"NCT06889649","phase":"PHASE2","title":"SABR Combined with Axitinib and Toripalimab in Recurrent or Metastatic RCC","status":"RECRUITING","sponsor":"Peking University First Hospital","startDate":"2019-01-01","conditions":"Radiation Therapy, Targeted Therapy, Immunotherapy","enrollment":30},{"nctId":"NCT00828919","phase":"NA","title":"Continuing Access to Axitinib (A406- AG- 013736 ) For Patients Previously Receiving AG 013736 In Clinical Trials","status":"COMPLETED","sponsor":"Pfizer","startDate":"2003-03-07","conditions":"Solid Tumors","enrollment":52},{"nctId":"NCT01693822","phase":"PHASE2","title":"A Phase II Study of Axitinib in Patients With Metastatic Renal Cell Cancer Unsuitable for Nephrectomy","status":"COMPLETED","sponsor":"Institute of Cancer Research, United Kingdom","startDate":"2012-10","conditions":"Clear-cell Metastatic Renal Cell Carcinoma","enrollment":65},{"nctId":"NCT02636725","phase":"PHASE2","title":"Axitinib and Pembrolizumab in Subjects With Advanced Alveolar Soft Part Sarcoma and Other Soft Tissue Sarcomas","status":"COMPLETED","sponsor":"Jonathan Trent, MD, PhD","startDate":"2016-04-19","conditions":"Alveolar Soft Part Sarcoma, Soft Tissue Sarcomas","enrollment":33},{"nctId":"NCT05096390","phase":"PHASE2","title":"Axitinib +/- Pembrolizumab in First Line Treatment of mPRCC","status":"RECRUITING","sponsor":"Centre Leon Berard","startDate":"2022-06-01","conditions":"Papillary Renal Cell Carcinoma Type 2","enrollment":72},{"nctId":"NCT03386929","phase":"PHASE1, PHASE2","title":"Survival Prolongation by Rationale Innovative Genomics","status":"TERMINATED","sponsor":"Worldwide Innovative Network Association","startDate":"2017-11-29","conditions":"Non-small Cell Lung Cancer Metastatic, Non-small Cell Lung Cancer Stage IIIB","enrollment":15},{"nctId":"NCT04180995","phase":"PHASE2","title":"Toripalimab in Combination With Axitinib in Patients With Localized Mucosal Melanoma","status":"UNKNOWN","sponsor":"Peking University Cancer Hospital & Institute","startDate":"2019-08-06","conditions":"Mucosal Melanoma","enrollment":30},{"nctId":"NCT03494816","phase":"PHASE2","title":"Study of Axitinib for Reducing Extent of Venous Tumour Thrombus in Renal Cancer With Venous Invasion","status":"COMPLETED","sponsor":"Scottish Clinical Trials Research Unit","startDate":"2017-12-15","conditions":"Renal Cell Carcinoma, Metastatic Renal Cell Carcinoma, Non-metastatic Renal Cell Carcinoma","enrollment":24},{"nctId":"NCT01140737","phase":"PHASE2","title":"A Study of Axitinib in Patients With Advanced Angiosarcoma and Other Soft Tissue Sarcomas","status":"COMPLETED","sponsor":"Sheffield Teaching Hospitals NHS Foundation Trust","startDate":"2010-08-31","conditions":"Soft Tissue Sarcoma","enrollment":145},{"nctId":"NCT04698213","phase":"PHASE2","title":"Avelumab Plus Intermittent Axitinib in Previously Untreated Patients With Metastatic Renal Cell Carcinoma","status":"UNKNOWN","sponsor":"Consorzio Oncotech","startDate":"2020-10-07","conditions":"Renal Carcinoma Metastatic","enrollment":75},{"nctId":"NCT01999972","phase":"PHASE1","title":"A Phase 1b Study Of Axitinib In Combination With Crizotinib In Patients With Advanced Solid Tumors","status":"COMPLETED","sponsor":"Pfizer","startDate":"2014-02-26","conditions":"Advanced Solid Tumors","enrollment":50},{"nctId":"NCT04355156","phase":"PHASE2","title":"Axitinib Monotherapy With Early Dynamic Contrast Enhanced Ultrasound Monitoring in Chemorefractory Third Line Metastatic Colorectal Cancer","status":"COMPLETED","sponsor":"Imperial College London","startDate":"2012-09-17","conditions":"Colorectal Cancer","enrollment":52},{"nctId":"NCT03941795","phase":"PHASE2","title":"Phase II Study in the Treatment of Patients With Advanced Mucinous Melanoma","status":"UNKNOWN","sponsor":"Peking University Cancer Hospital & Institute","startDate":"2019-11-11","conditions":"Advanced Mucosal Melanoma","enrollment":99},{"nctId":"NCT01490866","phase":"PHASE2","title":"A Trial of Single Agent Axitinib as Maintenance Therapy for Patients With First Line Metastatic Colorectal Cancer (mCRC)","status":"COMPLETED","sponsor":"SCRI Development Innovations, LLC","startDate":"2012-01","conditions":"Colorectal Cancer","enrollment":70},{"nctId":"NCT00219557","phase":"PHASE2","title":"AG-013736 In Combination With Gemcitabine Versus Gemcitabine Alone For Patients With Metastatic Pancreatic Cancer","status":"COMPLETED","sponsor":"Pfizer","startDate":"2005-07-05","conditions":"Pancreatic Neoplasms","enrollment":111},{"nctId":"NCT01210495","phase":"PHASE2","title":"Axitinib For The Treatment Of Advanced Hepatocellular Carcinoma","status":"COMPLETED","sponsor":"Pfizer","startDate":"2010-12-06","conditions":"Hepatocellular Carcinoma","enrollment":224},{"nctId":"NCT02560012","phase":"PHASE2","title":"Personalized Targeted Inhibitors Treatment in Renal Cell Cancer","status":"TERMINATED","sponsor":"The University of Texas Health Science Center, Houston","startDate":"2016-01-04","conditions":"Carcinoma, Renal Cell","enrollment":4},{"nctId":"NCT01435122","phase":"PHASE2","title":"A Study of Axitinib in Advanced Carcinoid Tumors","status":"COMPLETED","sponsor":"H. Lee Moffitt Cancer Center and Research Institute","startDate":"2011-10-25","conditions":"Carcinoid Tumor","enrollment":30},{"nctId":"NCT00389441","phase":"PHASE2","title":"Study Of AG-013736 In Patients With 131I-Refractory Thyroid Cancer","status":"COMPLETED","sponsor":"Pfizer","startDate":"2006-12","conditions":"Thyroid Neoplasms","enrollment":52},{"nctId":"NCT00600821","phase":"PHASE2","title":"A Study Of AG-013736 (Axitinib) Or Bevacizumab (Avastin) In Combination With Paclitaxel And Carboplatin In Patients With Advanced Lung Cancer.","status":"COMPLETED","sponsor":"Pfizer","startDate":"2008-04","conditions":"Non-Small-Cell Lung Carcinoma, Adenocarcinoma","enrollment":118},{"nctId":"NCT00735904","phase":"PHASE2","title":"Trial Of AG-013736, Cisplatin, And Gemcitabine For Patients With Squamous Non-Small Cell Lung Cancer","status":"COMPLETED","sponsor":"Pfizer","startDate":"2008-12","conditions":"Carcinoma, Non-Small-Cell Lung (NSCLC)","enrollment":38},{"nctId":"NCT00094055","phase":"PHASE2","title":"Study of the Anti-angiogenesis Agent AG-013736 in Patients With Metastatic Thyroid Cancer","status":"COMPLETED","sponsor":"Pfizer","startDate":"2004-09","conditions":"Thyroid Neoplasms","enrollment":60},{"nctId":"NCT00094094","phase":"PHASE2","title":"Anti-angiogenesis Agent AG-013736 in Patients With Advanced Non-Small Cell Lung Cancer","status":"COMPLETED","sponsor":"Pfizer","startDate":"2005-02","conditions":"Lung Neoplasms, Carcinoma, Non-small Cell Lung","enrollment":32},{"nctId":"NCT00692341","phase":"PHASE1","title":"Evaluation Of Hepatic Impairment On AG-013736 Pharmacokinetics","status":"COMPLETED","sponsor":"Pfizer","startDate":"2008-05","conditions":"Hepatic Insufficiency","enrollment":24},{"nctId":"NCT00454649","phase":"PHASE1","title":"Investigational Agent AG-013736 In Combinations With Standard Of Care Treatments For Patient's With Advanced Solid Tumor","status":"COMPLETED","sponsor":"Pfizer","startDate":"2005-12","conditions":"Neoplasms","enrollment":102},{"nctId":"NCT00949624","phase":"PHASE1","title":"CP-868,596 And CP-868,596 Plus AG-013736 In Combination With Docetaxel In Advanced Solid Tumors","status":"COMPLETED","sponsor":"Arog Pharmaceuticals, Inc.","startDate":"2005-12","conditions":"Advanced Solid Tumors","enrollment":50},{"nctId":"NCT01441388","phase":"PHASE1","title":"A Study Of Crizotinib Plus VEGF Inhibitor Combinations In Patients With Advanced Solid Tumors.","status":"WITHDRAWN","sponsor":"Pfizer","startDate":"2011-12","conditions":"Carcinoma, Renal Cell, Glioblastoma, Carcinoma, Hepatocellular","enrollment":""},{"nctId":"NCT01020136","phase":"PHASE1","title":"A Bioequivalence Study Of AG-013736 Tablets Under Fed Conditions In Healthy Volunteers","status":"COMPLETED","sponsor":"Pfizer","startDate":"2010-01","conditions":"Healthy Volunteer","enrollment":42},{"nctId":"NCT00905814","phase":"PHASE1","title":"A Bioequivalence Study Of AG-013736 Tablets In Healthy Volunteers","status":"COMPLETED","sponsor":"Pfizer","startDate":"2009-07","conditions":"Healthy Volunteers","enrollment":60},{"nctId":"NCT00918632","phase":"PHASE1","title":"Food Effect Study Of AG-013736 In Healthy Volunteers","status":"COMPLETED","sponsor":"Pfizer","startDate":"2009-06","conditions":"Healthy Volunteers","enrollment":30}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":5,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_1","status":"active","brandName":"Axitinib Tablets","genericName":"Axitinib Tablets","companyName":"Nanjing Leads Biolabs Co.,Ltd","companyId":"nanjing-leads-biolabs-co-ltd","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Axitinib is a selective inhibitor of vascular endothelial growth factor receptors (VEGFR-1, VEGFR-2, and VEGFR-3). Used for Advanced renal cell carcinoma.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}